With Dedication to this Mission - We are focused on bringing significantly better treatments to cancer patients and are therefore data-driven with the goal of maximizing patient benefit. Integrity - We are a selfless, focused team that values keeping our word and always doing the right thing.
Humor and Fun - We celebrate wins big or small and embrace having fun, using levity to de-escalate stressful or high-pressure situations and enable the development of the best solutions.Ownership and Accountability - Everyone is a leader at Infinity. We delegate tasks and empower others to succeed, while also working to address issues individually and collectively to ensure positive future results.
Humor and Fun - We celebrate wins big or small and embrace having fun, using levity to de-escalate stressful or high-pressure situations and enable the development of the best solutions.Ownership and Accountability - Everyone is a leader at Infinity. We delegate tasks and empower others to succeed, while also working to address issues individually and collectively to ensure positive future results.
Services
Adelene Perkins serves as Infinity's chief executive officer and Infinity's chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Before serving as CEO, Ms. Perkins served as Infinity's President, a position she held since 2008.
Dr. Agresta has an established track record of global clinical drug development in solid tumors and hematologic malignancies, including recent approval of multiple cancer medicines. Dr. Agresta is currently Chief Medical Officer of Foghorn Therapeutics.
Prior to Foghorn, Dr. Agresta served as Chief Medical Officer of Infinity where he led the company's clinical strategy including the design of MARIO-3 and MARIO-275, Infinity's Phase 2 clinical studies IPI-549.Prior to Infinity, Dr. Agresta was vice president and head of clinical development at Agios Pharmaceuticals, Inc.
Prior to Foghorn, Dr. Agresta served as Chief Medical Officer of Infinity where he led the company's clinical strategy including the design of MARIO-3 and MARIO-275, Infinity's Phase 2 clinical studies IPI-549.Prior to Infinity, Dr. Agresta was vice president and head of clinical development at Agios Pharmaceuticals, Inc.
D., is a thought leader in myeloid cell biology and serves as the Christopher M. Davis Professor in Cancer Research and Program Leader, Immunology, Microenvironment, and Metastasis at the Wistar Institute in Philadelphia and as the Wistar Professor at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania.
Research has demonstrated that PI3K-gamma plays an important role in maintaining the immunosuppressive nature of tumor-associated macrophages within the tumor microenvironment (TME) and myeloid-derived suppressor cells (MDSCs).
Targeting these pro-tumor, immunosuppressive cells represents an emerging approach within the field of cancer immunotherapy, and inhibition of PI3K-gamma by eganelisib represents a novel approach to targeting this immunosuppressive microenvironment.
Targeting these pro-tumor, immunosuppressive cells represents an emerging approach within the field of cancer immunotherapy, and inhibition of PI3K-gamma by eganelisib represents a novel approach to targeting this immunosuppressive microenvironment.
Patients are waiting, and Infinity is ready to help. We are a data-driven, people-centric company focused on the goal of bringing significantly better treatments to patients. A clinical trial is a carefully designed research study that brings innovative medicines to people with a particular disease or condition.
Reviews
Be the first to review Industrial Products International.
Write a Review
